文献速递肝病消化道肿瘤与早癌

非增强简化MRI与超声作为肝细胞癌监测方式的比较

Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.
PubMed 文献 · J Hepatol · 2024-04-16

这项前瞻性多中心队列研究纳入208例年肝细胞癌风险大于5%的患者,随访30个月。年度非增强简化MRI(NC-AMRI)的敏感性为71.0%(22/31),略高于半年一次超声的45.2%(14/31;p=0.077);NC-AMRI的诊断产出显著更高(4.26% vs 1.43%,p<0.001),假转诊率相似(2.91% vs 3.06%,p=0.885)。模拟交替使用超声与NC-AMRI每6个月一次,敏感性为83.9%(26/31),显著超过半年一次超声(p=0.006)。

要点

  • 在高危患者中,年度NC-AMRI的敏感性(71.0%)略高于半年一次超声(45.2%),差异未达统计学显著(p=0.077)。
  • NC-AMRI的诊断产出显著高于超声(4.26% vs 1.43%,p<0.001),假转诊率相似(2.91% vs 3.06%,p=0.885)。
  • 模拟交替使用超声与NC-AMRI每6个月一次,敏感性为83.9%(26/31),显著超过半年一次超声(p=0.006)。

核心结论

  • 年度NC-AMRI在高危患者中检测肝细胞癌的敏感性略高于半年一次超声。
  • 年度NC-AMRI的诊断产出显著高于半年一次超声,且未增加假转诊率。
  • 交替使用超声与NC-AMRI每6个月一次可能是高危患者的最佳监测策略。

研究设计与样本

  • 前瞻性多中心队列研究,纳入2015年10月至2017年4月间估计年肝细胞癌风险大于5%的参与者。
  • 参与者接受6轮肝细胞癌监测,间隔6个月;在第1、3、5轮同时进行超声和NC-AMRI,在第2、4、6轮仅进行超声。
  • 共208例参与者,随访30个月,进行了980次超声检查和516次NC-AMRI检查。

主要发现

  • 共31例参与者诊断为34个肝细胞癌,其中20个(64.5%)为极早期,11个(35.5%)为早期。
  • 年度NC-AMRI的敏感性为71.0%(22/31),半年一次超声的敏感性为45.2%(14/31),p=0.077。
  • NC-AMRI的诊断产出为4.26%,超声为1.43%,p<0.001。
  • NC-AMRI的假转诊率为2.91%,超声为3.06%,p=0.885。
  • 模拟交替使用超声与NC-AMRI每6个月一次的敏感性为83.9%(26/31),显著超过半年一次超声(p=0.006)。

临床怎么用

  • 当前指南允许在超声不足以满足监测需求的患者中使用MRI作为肝细胞癌监测工具。
  • 作者认为,交替使用超声与非增强简化MRI每6个月一次可能是高危患者的最佳监测策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ultrasound (US) is recommended for HCC surveillance in high-risk patients but has limited performance in detecting early-stage HCC. We aimed to compare the diagnostic performance of biannual US and annual non-contrast abbreviated magnetic resonance imaging (NC-AMRI) as HCC surveillance modalities in high-risk patients. METHODS: This prospective, multicenter cohort study enrolled participants with an estimated annual risk of HCC greater than 5% between October 2015 and April 2017. Participants underwent six rounds of HCC surveillance at 6-month intervals, with both US and NC-AMRI at rounds 1, 3, and 5, and only US at rounds 2, 4, and 6. The sensitivity, diagnostic yield (DY), and false referral rate (FRR) for HCC detection by US and NC-AMRI were compared. RESULTS: In total, 208 participants underwent 980 US and 516 NC-AMRI examinations during 30 months of follow-up. Among them, 34 HCCs were diagnosed in 31 participants, with 20 (64.5%) classified as very early-stage and 11 (35.5%) as early-stage HCC. The sensitivity of annual NC-AMRI (71.0%, 22/31) was marginally higher than that of biannual US (45.2%, 14/31; p = 0.077). NC-AMRI showed a significantly higher DY than US (4.26% vs. 1.43%, p <0.001), with a similar FRR (2.91% vs. 3.06%, p = 0.885). A simulation of alternating US and NC-AMRI at 6-month intervals yielded a sensitivity of 83.9% (26/31), significantly exceeding that of biannual US (p = 0.006). CONCLUSIONS: Annual NC-AMRI showed a marginally higher sensitivity than biannual US for HCC detection in high-risk patients. The DY of annual NC-AMRI was significantly higher than that of biannual US, without increasing the FRR. Thus, alternating US and NC-AMRI at 6-month intervals could be an optimal surveillance strategy for high-risk patients. IMPACT AND IMPLICATIONS: Current guidelines permit the use of magnetic resonance imaging (MRI) as a surveillance tool for hepatocellular carcinoma in patients in whom ultrasonography (US) is inadequate. However, the specific indications, imaging sequences, and intervals for MRI surveillance remain unclear. In our study, we found that annual non-contrast abbreviated MRI exhibited marginally higher sensitivity and significantly better diagnostic yield than biannual US in patients at high risk of hepatocellular carcinoma. Alternating US and non-contrast abbreviated MRI at 6-month intervals led to significantly improved sensitivity compared to biannual US, making it a potentially optimal surveillance strategy for high-risk patients. GOV IDENTIFIER: NCT02551250.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim DH, Yoon JH, Choi MH, et al. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC. J Hepatol. 2024. PMID: 38636849. doi:10.1016/j.jhep.2024.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。